

# References

## Cover Story—Ketamine: The Second Act

1. Ash L (February 11, 2024) Ketamine lifted the veil of my depression. Los Angeles Times; available from: <https://www.latimes.com/opinion/story/2024-02-11/ketamine-treatment-depression-psychedelics>.
2. Mion G (2017) History of anesthesia: The ketamine story—past, present, and future. *Eur J Anaesthesiol* **34(9)**: 574–575.
3. Li L and Vlisides P E (2016) Ketamine: 50 years of modulating the mind. *Front Hum Neurosci* **10**: 612. doi: [10.3389/fnhum.2016.00612](https://doi.org/10.3389/fnhum.2016.00612).
4. Zanos P, Moaddel R, Morris P J, Riggs, L M, Highland J N, Georgiou P, Pereira E F R, Albuquerque E X, Thomas C J, Zarate C A Jr, and Gould T D (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. *Pharmacol Rev* **70(3)**: 621–660.
5. Domino E F, Chodoff P, and Corssen G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. *Clin Pharmacol Ther* **6(3)**: 279–291.
6. *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (Brunton LL and Knollmann BC, eds.) 14<sup>th</sup> Edition, McGraw Hill, New York.
7. Torrice M (2020) Ketamine is revolutionizing antidepressant research, but we still don't know how it works. *Chem & Eng News* **98(3)**: 18–22.
8. Meisner R C (May 22, 2019) Ketamine for major depression: new tool, new questions. *Harvard Health Blog*; available from: <https://www.health.harvard.edu/blog/ketamine-for-major-depression-new-tool-new-questions-2019052216673>.
9. Williams N R, Heifets B D, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons D M, Rodriguez C I, and Schatzberg A F (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. *Am J Psychiatry* **175(12)**: 1205–1215.
10. Kelvey J (September 11, 2018) Ketamine works as a fast-acting antidepressant, but the full effects are still unknown. *Smithsonian Magazine*; available from: <https://www.smithsonianmag.com/science-nature/ketamine-works-fast-acting-antidepressant-full-effects-are-still-unknown-180970265>.
11. Abbasi J (2017) Ketamine minus the trip: new hope for treatment-resistant depression. *JAMA* **318(20)**: 1964–1966.
12. Sanders L (December 16, 2019) In 2019, a ketamine-based antidepressant raised hopes and concerns. *Science News*; available from: <https://www.sciencenews.org/article/ketamine-based-depression-drugs-top-science-stories-2019-yir>.
13. Duman R S and Aghajanian G K (2012) Synaptic dysfunction in depression: Potential therapeutic targets. *Science* **338(6103)**: 68–72.
14. Singh J B, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets W C, and Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. *Biological Psychiatry* **80**: 424–431.
15. Panico G (May 5, 2018) New phase 3 data show esketamine nasal spray demonstrated rapid improvements in depressive symptoms in patients with treatment-resistant depression. Janssen press release; available from: <https://www.jnj.com/media-center/press-releases/new-phase-3-data-show-esketamine-nasal-spray-demonstrated-rapid-improvements-in-depressive-symptoms-in-patients-with-treatment-resistant-depression>.
16. Medical Letter (2019) Esketamine nasal spray (Spravato) for treatment-resistant depression. *Medical Letter* **61(1569)**: 54–56.
17. Zarate C A, Singh J B, Carlson P J, Brutsche N E, Ameli R, Luckenbaugh D A, Charney D S, and Manji H K (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry* **63**: 856–864.
18. Berman R M, Cappiello A, Anand A, Oren D A, Heninger G R, Charney D S, and Krystal J H (2000) Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* **47**: 351–354.
19. Wilkinson S T, Howard D H, and Busch S H (2019) Psychiatric practice patterns and barriers to the adoption of esketamine. *JAMA* **322(11)**: 1039–1040.
20. Hinchcliffe J K, Stuart S A, Wood C M, Bartlett J, Kamenish K, Arban R, Thomas C W, Semlimbeyoglu A, Hurley S, Hengerer B, et al (January 10, 2024) Rapid-acting antidepressant drugs modulate affective bias in rats. *Sci Translat Med* **16(729)**: eadi2403. doi: [10.1126/scitranslmed.adi2403](https://doi.org/10.1126/scitranslmed.adi2403).
21. Wojtas A, Bysiek A, Wawrzczak-Bargiela A, Szych Z, Majcher-Maslanka I, Herian M, Mackowiak M, and Golembiowska K (2022) Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA, and rat behavior. *Intl J Mol Sci* **23(12)**: 6713. doi: [10.3390/ijms23126713](https://doi.org/10.3390/ijms23126713).
22. Winton R (June 26, 2024) Matthew Perry death inquiry nears end. Los Angeles Times; available from: <https://www.latimes.com/california/story/2024-06-26/matthew-perry-ketamine-death-investigation-nearing-conclusion>.

## Cover Story—Ketamine: The Second Act

- Walsh S (March 5, 2019) FDA approves new nasal spray medication for treatment-resistant depression; available only at certified doctor's office or clinic. *FDA news*; available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified>.
- Ionescu D F, Fu D-J, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets W C, Manji H, and Canuso C M (2021) Esketamine nasal spray for rapid reduction of depressive disorder who have active suicide ideation with intent: results of a Phase 3, double-blind, randomized study (ASPIRE II). *Intl J Neuropsychopharm* **24(1)**: 22–31.
- Medical Letter (2020) A new indication for esketamine nasal spray (Spravato). *Medical Letter* **62(1607)**: 151–152.
- Fu C-J, Ionescu D F, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets W C, and Canuso C M (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). *J Clin Psychiatry* **81(3)**: 19m13191.

## Advocacy Impact—We Are More Than an Isolated Event: Why Polysubstance Use Needs the Spotlight

- CDC. (2024, March 8). State Unintentional Drug Overdose Reporting System (SUDORS). Centers for Disease Control and Prevention. US Department of Health and Human Services. <https://www.cdc.gov/overdose-prevention/data-research/facts-stats/sudors-dashboard-fatal-overdose-data.html>.
- CDC. (2022, February 23). Polysubstance use facts. Centers for Disease Control and Prevention. <https://www.cdc.gov/stop-overdose/caring/polysubstance-use.html>.
  - Substance Abuse and Mental Health Services Administration. (2023). Drug Abuse Warning Network: Findings from Drug-Related Emergency Department Visits, 2022 (HHS Publication No. PEP23-07-03-001). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from <https://www.samhsa.gov/data>.
  - Agency for Healthcare Research and Quality. (2023, October 7). Alarming Trends in Substance Use-Related Health Outcomes. What Can Primary Care Physicians Do? Substance Use-Related Health Outcome Trends | The Academy. <https://integrationacademy.ahrq.gov/news-and-events/news/alarming-trends-substance-use-related-health-outcomes-what-can-primary-care>.
  - Substance Abuse and Mental Health Services Administration (SAMHSA). (2023, November 13). HHS, Samhsa Release 2022 National Survey on Drug Use and Health Data. SAMHSA: Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/newsroom/press-announcements/20231113/hhs-samhsa-release-2022-nsduh-data>.
  - CDC. (2023, August 8). Opioid Data Analysis and Resources. Centers for Disease Control and Prevention. <https://www.cdc.gov/overdose-prevention>.
  - Crummy, E. A., O'Neal, T. J., Baskin, B. M., & Ferguson, S. M. (2020, June 15). One is not enough: Understanding and modeling polysubstance use. *Frontiers in Neuroscience*, **14**: 569. doi: [10.3389/fnins.2020.00569](https://doi.org/10.3389/fnins.2020.00569).
  - Health Policy Institute. (2019, February 13). Substance Abuse: Facing the Costs. <https://hpi.georgetown.edu/abuse>.
  - Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report>.
  - Compton, W.M., Valentino, R.J. & DuPont, R.L. Polysubstance use in the U.S. opioid crisis. *Mol Psychiatry* **26**: 41–50 (2021). doi: [10.1038/s41380-020-00949-3](https://doi.org/10.1038/s41380-020-00949-3).

# References

## Advocacy Impact—Accessibility of Treatments for Opioid Use Disorder in El Paso, Texas

1. DEA Museum. (2021). Opium Poppy. [online] Available at: <https://museum.dea.gov/exhibits/online-exhibits/cannabis-coca-and-poppy-natures-addictive-plants/opium-poppy>.
2. CDC, (2024). Opioids—Commonly Used Terms. [online] Available at: <https://www.cdc.gov/overdose-prevention/glossary>.
3. CDC, (2024). Risks and How to Reduce Them. [online] Available at: <https://www.cdc.gov/overdose-prevention/manage-treat-pain/reduce-risks.html>.
4. Psychiatry.org. (2024). Opioid Use Disorder. [online] Available at: <https://www.psychiatry.org/patients-families/opioid-use-disorder>.
5. NIH, (2024). Withdrawal Management. [online] Available at: <https://www.ncbi.nlm.nih.gov/books/NBK310652>.
6. NIH. (2023). Only 1 in 5 U.S. adults with opioid use disorder received medications to treat it in 2021 | National Institute on Drug Abuse. [online] National Institute on Drug Abuse. Available at: <https://nida.nih.gov/news-events/news-releases/2023/08/only-1-in-5-us-adults-with-opioid-use-disorder-received-medications-to-treat-it-in-2021>.
7. Jones, C.M., Han, B., Baldwin, G.T., Einstein, E.B. and Compton, W.M. (2023). Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. *JAMA Netw Open*. **2023;6(8)**: e2327488. doi: [10.1001/jamanetworkopen.2023.27488](https://doi.org/10.1001/jamanetworkopen.2023.27488).
8. CDC, (2024). Opioid Use Disorder: Preventing and Treating. [online] Available at: <https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-diagnosis.html>.
9. Mancher, M. and Leshner, A.I. (2019). Barriers to Broader Use of Medications to Treat Opioid Use Disorder. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK541389>.
10. FDA, (2023). FDA Approves First Over-the-Counter Naloxone Nasal Spray. [online] U.S. Food and Drug Administration. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray>.
11. SAMHSA.gov. (2023). Harm Reduction. [online] Available at: <https://www.samhsa.gov/find-help/harm-reduction>.
12. Census Bureau QuickFacts. (2023). QuickFacts: El Paso city, Texas; El Paso County, Texas. [online] Available at: <https://www.census.gov/quickfacts/fact/table/elpasocitytexas.elpasocountytexas/PST045223>.
13. NASEN (2019). NASEN | North America Syringe Exchange Network: NASEN Directory. [online] Nasen.org. Available at: <https://www.nasen.org> [Accessed 22 Apr. 2024].
14. Mendoza, M. (2023). Bexar county has the only legal needle exchange in the state. [online] *WAOI*. Available at: <https://news4sanantonio.com/news/local/bexar-county-has-the-only-legal-needle-exchange-in-the-state-overdoses-blood-born-diseases-prevention>.
15. Community Health Partnership. (2022). Substance Use Issues—Community Health Partnership. [online] Available at: <https://www.ppchp.org/substance-use-issues>.
16. René Kladzyk (2022). Narcan on hand: EPPD patrol officers don't carry Narcan amid skyrocketing overdose deaths. [online] *El Paso Matters*. Available at: <https://elpasomatters.org/2022/03/14/narcan-on-hand-eppd-patrol-officers-dont-carry-narcan-amid-skyrocketing-overdose-deaths>.
17. Jackson, J. (2022). UTEP campus police do not carry Narcan, despite UT System approval—Open Campus. [online] *Open Campus*. Available at: <https://www.opencampusmedia.org/2022/03/21/utep-campus-police-do-not-carry-narcan-despite-ut-system-approval>.
18. CDC, (2024). Lifesaving Naloxone. [online] Available at: <https://www.cdc.gov/stop-overdose/caring/naloxone.html>.
19. Rando J, Broering D, Olson JE, Marco C, Evans SB (2015). Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. *Am J Emerg Med*. **33(9)**: 1201-4. doi: [10.1016/j.ajem.2015.05.022](https://doi.org/10.1016/j.ajem.2015.05.022).
20. Recoveryalliance.net. (2024). Project Punto de Partida. [online] Available at: <https://www.recoveryalliance.net/puntodepartida.html> [Accessed 22 Apr. 2024].
21. Flórez, K.R., Derose, K.P., Breslau, J. et al. Acculturation and Drug Use Stigma Among Latinos and African Americans: An Examination of a Church-Based Sample. *J Immigrant Minority Health* **17**, 1607–1614 (2015). doi: [10.1007/s10903-015-0161-9](https://doi.org/10.1007/s10903-015-0161-9).